Published in Blood on September 15, 2000
Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood (2008) 2.76
Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood (2006) 2.38
The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood (2011) 2.23
Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor. Proc Natl Acad Sci U S A (2003) 1.80
Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood (2012) 1.67
STAT5 signaling is required for the efficient induction and maintenance of CML in mice. Blood (2006) 1.63
A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell (2013) 1.59
Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood (2011) 1.52
Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells. Leuk Lymphoma (2012) 1.40
Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol (2009) 1.40
Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J Immunol (2008) 1.15
Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer. Clin Cancer Res (2007) 1.14
Oncogenic signaling: new insights and controversies from chronic myeloid leukemia. J Exp Med (2007) 1.13
FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis. Biochim Biophys Acta (2007) 1.13
Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells. J Exp Med (2005) 1.12
STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia. Oncotarget (2012) 1.12
Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2. Mol Cancer Ther (2014) 1.09
Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma. PLoS One (2010) 1.06
MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825. Blood (2007) 1.05
Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. Blood (2005) 1.03
A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors. Cancer Res (2010) 1.02
Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells. Blood (2007) 0.97
Signal transducers and activators of transcription 5 contributes to erythropoietin-mediated neuroprotection against hippocampal neuronal death after transient global cerebral ischemia. Neurobiol Dis (2006) 0.97
Direct regulation of BCL-2 by FLI-1 is involved in the survival of FLI-1-transformed erythroblasts. EMBO J (2002) 0.92
STAT signaling in the pathogenesis and treatment of myeloid malignancies. JAKSTAT (2012) 0.92
Bcl-xL silencing induces alterations in hsa-miR-608 expression and subsequent cell death in A549 and SK-LU1 human lung adenocarcinoma cells. PLoS One (2013) 0.91
An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259. Oncogene (2008) 0.88
Differentiating the roles of STAT5B and STAT5A in human CD4+ T cells. Clin Immunol (2013) 0.87
Suppression of interferon (IFN)-inducible genes and IFN-mediated functional responses in BCR-ABL-expressing cells. J Biol Chem (2008) 0.87
Indirubin derivatives induce apoptosis of chronic myelogenous leukemia cells involving inhibition of Stat5 signaling. Mol Oncol (2012) 0.86
Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR-CML cell lines? Biosci Rep (2013) 0.85
A critical role of CDKN3 in Bcr-Abl-mediated tumorigenesis. PLoS One (2014) 0.84
Following the cytokine signaling pathway to leukemogenesis: a chronology. J Clin Invest (2008) 0.84
A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis. Neoplasia (2012) 0.83
BCR-ABL affects STAT5A and STAT5B differentially. PLoS One (2014) 0.83
Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors. Stem Cells Transl Med (2014) 0.82
The synthetic α-bromo-2',3,4,4'-tetramethoxychalcone (α-Br-TMC) inhibits the JAK/STAT signaling pathway. PLoS One (2014) 0.81
Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia. PLoS One (2014) 0.81
Contributions of the RhoGEF activity of p210 BCR/ABL to disease progression. Leukemia (2012) 0.80
Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (BET) protein function. Nucleic Acids Res (2015) 0.80
Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts. Wien Klin Wochenschr (2003) 0.79
Loss of Bcl-x in Ph+ B-ALL increases cellular proliferation and does not inhibit leukemogenesis. Blood (2008) 0.79
SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells. Cancer Biol Ther (2014) 0.79
Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia Cells. Cancers (Basel) (2015) 0.79
Signal transducer and activator of transcription STAT5 is recruited to c-Myc super-enhancer. BMC Mol Biol (2016) 0.78
Loss of the xeroderma pigmentosum group B protein binding site impairs p210 BCR/ABL1 leukemogenic activity. Blood Cancer J (2013) 0.77
Structure-Based Screen Identifies a Potent Small Molecule Inhibitor of Stat5a/b with Therapeutic Potential for Prostate Cancer and Chronic Myeloid Leukemia. Mol Cancer Ther (2015) 0.77
STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. Leukemia (2013) 0.76
Hsp90 Inhibitors for the Treatment of Chronic Myeloid Leukemia. Leuk Res Treatment (2015) 0.75
The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL. Sci Rep (2016) 0.75
The Chemopreventive Phytochemical Moringin Isolated from Moringa oleifera Seeds Inhibits JAK/STAT Signaling. PLoS One (2016) 0.75
Novel iodoacetamido benzoheterocyclic derivatives with potent antileukemic activity are inhibitors of STAT5 phosphorylation. Eur J Med Chem (2015) 0.75
Identification of novel SAR properties of the Jak2 small molecule inhibitor G6: significance of the para-hydroxyl orientation. Bioorg Med Chem Lett (2011) 0.75
MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors. Nat Genet (2000) 3.82
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene (2001) 3.36
Granulocyte colony-stimulating factor and its receptor. Blood (1991) 3.24
Leukocyte adhesion molecule-1 (LAM-1, L-selectin) interacts with an inducible endothelial cell ligand to support leukocyte adhesion. J Immunol (1991) 3.05
Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes. J Clin Invest (1985) 2.77
Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J Exp Med (1996) 2.68
cdc2 gene expression at the G1 to S transition in human T lymphocytes. Science (1990) 2.59
Immobilization of Notch ligand, Delta-1, is required for induction of notch signaling. J Cell Sci (2000) 2.57
JAK2 associates with the beta c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region. Mol Cell Biol (1994) 2.55
Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion. J Clin Invest (1988) 2.46
Two functional domains in the phagocyte membrane glycoprotein Mo1 identified with monoclonal antibodies. J Immunol (1986) 2.45
Characterization of an antigen expressed by human natural killer cells. J Immunol (1983) 2.44
Hematopoietic growth factors signal through the formation of reactive oxygen species. Blood (1999) 2.43
Relationship of oligomerization to enzymatic and DNA-binding properties of the SV40 large T antigen. Cell (1982) 2.35
Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood (1991) 2.35
Expression of myeloid differentiation antigens on normal and malignant myeloid cells. J Clin Invest (1981) 2.34
AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer (2006) 2.33
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med (1988) 2.23
Independent regulation of human D-type cyclin gene expression during G1 phase in primary human T lymphocytes. J Biol Chem (1993) 2.23
The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem (2000) 1.98
Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Exp Hematol (1993) 1.98
The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression. Proc Natl Acad Sci U S A (1992) 1.94
Expression of interleukin 2 receptors and binding of interleukin 2 by gamma interferon-induced human leukemic and normal monocytic cells. J Exp Med (1985) 1.87
A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res (1984) 1.85
Hypoxia potentiates Notch signaling in breast cancer leading to decreased E-cadherin expression and increased cell migration and invasion. Br J Cancer (2009) 1.85
Regulation of G1/S transition by cyclins D2 and D3 in hematopoietic cells. Proc Natl Acad Sci U S A (1993) 1.84
Tyrosine phosphorylation of p95Vav in myeloid cells is regulated by GM-CSF, IL-3 and steel factor and is constitutively increased by p210BCR/ABL. EMBO J (1995) 1.78
Regulation of leukocyte migration by activation of the leukocyte adhesion molecule-1 (LAM-1) selectin. Nature (1991) 1.76
Protein kinase activity associated with simian virus 40 T antigen. Proc Natl Acad Sci U S A (1979) 1.72
Measurements of the molecular size of the simian virus 40 large T antigen. J Virol (1978) 1.70
Expression and state of phosphorylation of the retinoblastoma susceptibility gene product in cycling and noncycling human hematopoietic cells. Proc Natl Acad Sci U S A (1990) 1.57
Morphologic and cytochemical characteristics of acute promyelocytic leukemia. Am J Hematol (1989) 1.54
Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo. Leukemia (2004) 1.54
Induction of monocyte migration by recombinant macrophage colony-stimulating factor. J Immunol (1988) 1.53
Autocrine secretion of GM-CSF in acute myeloblastic leukemia. Blood (1986) 1.53
Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood (2000) 1.51
Expression of the M-CSF (CSF-1) gene by human monocytes. Blood (1987) 1.49
Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene (2000) 1.47
Conservation of myeloid surface antigens on primate granulocytes. Blood (1983) 1.44
STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood (2000) 1.44
The role of focal adhesion kinase binding in the regulation of tyrosine phosphorylation of paxillin. J Biol Chem (1999) 1.44
Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet (1988) 1.43
Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem (1994) 1.43
BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. J Biol Chem (2000) 1.40
The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway. Oncogene (1996) 1.40
Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. Oncogene (1999) 1.39
Personnel Selection in the Army. Can Med Assoc J (1943) 1.39
A cost comparison of methohexital and propofol for ambulatory anesthesia. Anesth Analg (1999) 1.38
Constitutive expression of the granulocyte-macrophage colony-stimulating factor gene in acute myeloblastic leukemia. J Clin Invest (1987) 1.37
Psychoneurotics Discharged from the Canadian Army. Can Med Assoc J (1945) 1.37
The related adhesion focal tyrosine kinase forms a complex with paxillin in hematopoietic cells. J Biol Chem (1996) 1.37
The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl. J Biol Chem (1995) 1.36
Isolation of myeloid progenitor cells from peripheral blood of chronic myelogenous leukemia patients. Blood (1982) 1.35
ARG tyrosine kinase activity is inhibited by STI571. Blood (2001) 1.35
Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL. J Biol Chem (1994) 1.33
Differential expression of CD11b/CD18 (Mo1) and myeloperoxidase genes during myeloid differentiation. Blood (1989) 1.32
CD2 is involved in maintenance and reversal of human alloantigen-specific clonal anergy. J Exp Med (1994) 1.27
The bovine papillomavirus E6 protein binds to the LD motif repeats of paxillin and blocks its interaction with vinculin and the focal adhesion kinase. J Biol Chem (1997) 1.27
Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism. Blood (1988) 1.26
Ventromedial preoptic prostaglandin E2 activates fever-producing autonomic pathways. J Neurosci (1996) 1.25
Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood (1991) 1.24
BCR/ABL induces multiple abnormalities of cytoskeletal function. J Clin Invest (1997) 1.23
Effects of recombinant human granulocyte and macrophage colony-stimulating factors on signal transduction pathways in human granulocytes. J Immunol (1987) 1.23
Increased tyrosine phosphorylation of focal adhesion proteins in myeloid cell lines expressing p210BCR/ABL. Oncogene (1995) 1.23
Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cells. J Biol Chem (1997) 1.23
Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms. Leukemia (2011) 1.22
Granulocyte-macrophage colony-stimulating factor, interleukin-3, and steel factor induce rapid tyrosine phosphorylation of p42 and p44 MAP kinase. Blood (1992) 1.21
The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp Hematol (1995) 1.21
Drug resistance in mutant FLT3-positive AML. Oncogene (2010) 1.20
NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases. Leukemia (2010) 1.20
Regulation of granulocyte- and monocyte-colony stimulating factor mRNA levels in human blood monocytes is mediated primarily at a post-transcriptional level. J Biol Chem (1989) 1.19
Diagnosis and treatment of human leukemias and lymphomas utilizing monoclonal antibodies. Prog Hematol (1981) 1.19
Surface marker analysis of acute myeloblastic leukemia: identification of differentiation-associated phenotypes. Blood (1983) 1.19
p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene (1996) 1.19
Human granulocyte-macrophage colony-stimulating factor induces expression of the tumor necrosis factor gene by the U937 cell line and by normal human monocytes. J Clin Invest (1987) 1.18
Microinjection of a cyclooxygenase inhibitor into the anteroventral preoptic region attenuates LPS fever. Am J Physiol (1998) 1.17
Purification and characterization of fetal hematopoietic cells that express the common acute lymphoblastic leukemia antigen (CALLA). J Exp Med (1983) 1.16
Clonogenic cells in acute myeloblastic leukemia. Blood (1986) 1.16
NOTCH1-induced T-cell leukemia in transgenic zebrafish. Leukemia (2007) 1.15
Ontogeny of human hematopoietic cells: analysis utilizing monoclonal antibodies. J Immunol (1983) 1.14
Induction of proliferation of purified human myeloid progenitor cells: a rapid assay for granulocyte colony-stimulating factors. Blood (1984) 1.13
Idiopathic thrombocytopenia in association with extragonadal germ cell cancer. Ann Intern Med (1983) 1.12
Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro. Blood (1989) 1.12
Identification and initial characterization of a new low-molecular-weight virus-encoded T antigen in a line of simian virus 40-transformed cells. J Virol (1980) 1.11
The role of protein composition in specifying nuclear inclusion formation in polyglutamine disease. J Biol Chem (2001) 1.08
Independent regulation of M-CSF and G-CSF gene expression in human monocytes. Blood (1988) 1.07
p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene. J Biol Chem (1996) 1.07
Differential signaling after beta1 integrin ligation is mediated through binding of CRKL to p120(CBL) and p110(HEF1). J Biol Chem (1997) 1.07
Expression of normal monocyte-macrophage differentiation antigens on HL60 promyelocytes undergoing differentiation induced by leukocyte-conditioned medium or phorbol diester. Leuk Res (1981) 1.07
Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia (2011) 1.06
Regulation of the production and function of granulocytes and monocytes. Semin Hematol (1988) 1.06
Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. N Engl J Med (1987) 1.06
Brain armadillo protein delta-catenin interacts with Abl tyrosine kinase and modulates cellular morphogenesis in response to growth factors. J Neurosci Res (2002) 1.06
Expression of the macrophage colony-stimulating factor and c-fms genes in human acute myeloblastic leukemia cells. J Clin Invest (1988) 1.05
Smac mimetics: implications for enhancement of targeted therapies in leukemia. Leukemia (2010) 1.05
Notch receptors and hematopoiesis. Exp Hematol (2001) 1.05